Tara M. Strutt

Dr. Tara M. Strutt

Burnett School of Biomedical Sciences, University of Central Florida disabled, Orlando, FL 32816, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2018 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
DCDavid Alex Cronkite
David Alex Cronkite
Tara M. StruttTara M. Strutt
Tara M. Strutt
Inflammation plays an essential role in the control of pathogens and in shaping the ensuing adaptive immune responses. Traditionally, innate immunity has been described as a rapid response triggered through generic and nonspecific means that by definition lacks the ability to remember. Recently, it has become clear that some innate immune cells are epigenetically reprogrammed or “imprinted” by past experiences. These “trained” innate immune cells display altered inflammatory responses upon subsequent pathogen encounter. Remembrance of past pathogen encounters has classically been attributed to cohorts of antigen-specific memory T and B cells following the resolution of infection. During recall responses, memory T and B cells quickly respond by proliferating, producing effector cytokines, and performing various effector functions. An often-overlooked effector function of memory CD4 and CD8 T cells is the promotion of an inflammatory milieu at the initial site of infection that mirrors the primary encounter. This memory-conditioned inflammatory response, in conjunction with other secondary effector T cell functions, results in better control and more rapid resolution of both infection and the associated tissue pathology. Recent advancements in our understanding of inflammatory triggers, imprinting of the innate immune responses, and the role of T cell memory in regulating inflammation are discussed.

14 August 2019 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KMK. Kai McKinstry
K. Kai McKinstry
FAFahmida Alam
Fahmida Alam
VFValeria Flores-Malavet
Valeria Flores-Malavet
MNMate Z. Nagy
Mate Z. Nagy
SSStewart Sell
Stewart Sell
Tara M. StruttTara M. Strutt
Tara M. Strutt
Defining the most penetrating correlates of protective memory T cells is key for designing improved vaccines and T cell therapies. Here, we evaluate how interleukin (IL-2) production by memory CD4 T cells, a widely held indicator of their protective potential, impacts immune responses against murine influenza A virus (IAV). Unexpectedly, we show that IL-2-deficient memory CD4 T cells are more effective on a per cell basis at combating IAV than wild-type memory cells that produce IL-2. Improved outcomes orchestrated by IL-2-deficient cells include reduced weight loss and improved respiratory function that correlate with reduced levels of a broad array of inflammatory factors in the infected lung. Blocking CD70-CD27 signals to reduce CD4 T cell IL-2 production tempers the inflammation induced by wild-type memory CD4 T cells and improves the outcome of IAV infection in vaccinated mice. Finally, we show that IL-2 administration drives rapid and extremely potent lung inflammation involving NK cells, which can synergize with sublethal IAV infection to promote acute death. These results suggest that IL-2 production is not necessarily an indicator of protective CD4 T cells, and that the lung environment is particularly sensitive to IL-2-induced inflammation during viral infection. We show that memory CD4 T cell mediated protection against influenza A virus is independent of the signature multifunctional cytokine IL-2 that is thought to define the most protective memory cells. IL-2 deficient cells are more effective than wild-type memory cells on a per cell basis at combating IAV and drive tempered early innate inflammatory responses. Our studies define a clear and surprising role for IL-2 as a cytokine adjuvant within the lung that can synergize with virus driven acute inflammatory responses to cause morbidity during sublethal respiratory viral infection.


15 October 2016 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
Tara M. StruttTara M. Strutt
Tara M. Strutt
KMKarl McKinstry
Karl McKinstry
YKYi Kuang
Yi Kuang
CFCaroline M. Finn
Caroline M. Finn
JHJi Hae Hwang
Ji Hae Hwang
SSSusan L. Swain
Susan L. Swain
Memory T cells can often respond against pathogens that have evaded neutralizing Abs and are thus key to vaccine-induced protection, yet the signals needed to optimize their responses are unclear. In this study, we identify a dramatic and selective requirement for IL-6 to achieve optimal memory CD4 T cell recall following heterosubtypic influenza A virus (IAV) challenge of mice primed previously with wild-type or attenuated IAV strains. Through analysis of endogenous T cell responses and adoptive transfer of IAV-specific memory T cell populations, we find that without IL-6, CD4+, but not CD8+, secondary effector populations expand less and have blunted function and antiviral impact. Early and direct IL-6 signals to memory CD4 T cells are required to program maximal secondary effector responses at the site of infection during heterosubtypic challenge, indicating a novel role for a costimulatory cytokine in recall responses.

6 May 2020 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
FAFahmida Alam
Fahmida Alam
ASAyushi Singh
Ayushi Singh
VFValeria Flores-Malavet
Valeria Flores-Malavet
SSStewart Sell
Stewart Sell
ACAndrea Cooper
Andrea Cooper
Tara M. StruttTara M. Strutt
Tara M. Strutt
IL-2 is a pleotropic cytokine with potent pro- and anti-inflammatory effects. These divergent impacts can be directed in vivo by forming complexes of IL-2 and anti–IL-2 mAbs (IL-2C) to target IL-2 to distinct subsets of cells based on their expression of subunits of the IL-2R. In this study, we show that treatment of mice with a prototypical anti-inflammatory IL-2C, JES6-1–IL-2C, best known to induce CD25+ regulatory CD4 T cell expansion, surprisingly causes robust induction of a suite of inflammatory factors. However, treating mice infected with influenza A virus with this IL-2C reduces lung immunopathology. We compare the spectrum of inflammatory proteins upregulated by pro- and anti-inflammatory IL-2C treatment and uncover a pattern of expression that reveals potentially beneficial versus detrimental aspects of the influenza-associated cytokine storm. Moreover, we show that anti-inflammatory IL-2C can deliver survival signals to CD4 T cells responding to influenza A virus that improve their memory fitness, indicating a novel application of IL-2 to boost pathogen-specific T cell memory while simultaneously reducing immunopathology.

25 March 2022 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
KDKunal Dhume
Kunal Dhume
CFCaroline M. Finn
Caroline M. Finn
PDPriyadharshini Devarajan
Priyadharshini Devarajan
ASAyushi Singh
Ayushi Singh
JTJoanne D. Tejero
Joanne D. Tejero
KMKarl McKinstry
Karl McKinstry
Optimal transcriptional programming needed for CD4 T cells to protect against influenza A virus (IAV) is unclear. Most IAV-primed CD4 T cells fit Th1 criteria. However, cells deficient for the Th1 “master regulator,” T-bet, although marked by reduced Th1 identity, retain robust protective capacity. In this study, we show that T-bet’s paralog, Eomesodermin (Eomes), is largely redundant in the presence of T-bet but is essential for the residual Th1 attributes of T-bet–deficient cells. Cells lacking both T-bet and Eomes instead develop concurrent Th17 and Th2 responses driven by specific inflammatory signals in the infected lung. Furthermore, the transfer of T-bet– and Eomes-deficient Th17, but not Th2, effector cells protects mice from lethal IAV infection. Importantly, these polyfunctional Th17 effectors do not display functional plasticity in vivo promoting gain of Th1 attributes seen in wild-type Th17 cells, which has clouded evaluation of the protective nature of Th17 programming in many studies. Finally, we show that primary and heterosubtypic IAV challenge is efficiently cleared in T-bet– and Eomes double-deficient mice without enhanced morbidity despite a strongly Th17-biased inflammatory response. Our studies thus demonstrate unexpectedly potent antiviral capacity of unadulterated Th17 responses against IAV, with important implications for vaccine design.